Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure

Critical Care Medicine

Volumn 35, Issue 10, 2007, Pages 2375-2382

  Martin, Kenneth ^a,b,c   Borgel, Delphine ^a,b,c   Lerolle, Nicolas ^a,b,c   Feys, Hendrik B ^d   Trinquart, Ludovic ^a,c   Vanhoorelbeke, Karen ^d   Deckmyn, Hans ^d   Legendre, Paulette ^a,e   Diehl, Jean Luc ^a,b,c   Baruch, Dominique ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

ADAMTS 13; Severe sepsis; Thrombosis; Von Willebrand factor

Indexed keywords

INTERLEUKIN 6; THROMBOMODULIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; HUMAN; INFLAMMATION; INTENSIVE CARE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SEPSIS; SURVIVAL; UNIVERSITY HOSPITAL; VASCULAR ENDOTHELIUM;

EID: 34748855578     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000284508.05247.B3     Document Type: Article

References (41)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
2. Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101:3765-3777
3. Rubin DB, Wiener-Kronish JP, Murray JF, et al: Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86:474-480
4. Ware LB, Eisner MD, Thompson BT, et al: Significance of Von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004; 170:766-772
5. Katayama T, Ikeda Y, Handa M, et al: Immunoneutralization of glycoprotein Ibalpha attenuates endotoxin-induced interactions of platelets and leukocytes with rat venular endothelium in vivo. Circ Res 2000; 86:1031-1037
6. Ruggeri ZM: Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1:1335-1342
7. Levy GG, Nichols WC, Lian EC, et al: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488-494
8. Dong J-f, Moake JL, Nolasco L, et al: ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100:4033-4039
9. Reiter RA, Varadi K, Turecek PL, et al: Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93:554-558
10. Mannucci PM, Canciani MT, Forza I, et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730-2735
11. Bianchi V, Robles R, Alberio L, et al: Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100:710-713
12. Ono T, Mimuro J, Madoiwa S, et al: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006; 107:528-534
13. Mannucci PM, Parolari A, Canciani MT, et al: Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery. J Thromb Haemost 2005; 3:397-399
14. Bernard GR, Vincent J-L, Laterre P-F, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
15. Borgel D, Clauser S, Bornstain C, et al: Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med 2006; 34:219-222
16. Fagon JY, Chastre J, Novara A, et al: Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: The ODIN model. Intensive Care Med 1993; 19:137-144
17. Knaus W, Draper E, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
18. Bellomo R, Kellum J, Ronco C: Acute renal failure: Time for consensus. Intensive Care Med 2001; 27:1685-1688
19. Bakhtiari K, Meijers JC, de Jonge E, et al: Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416-2421
20. Kokame K, Nobe Y, Kokubo Y, et al: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100
21. Feys HB, Liu F, Dong N, et al: ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006; 4:955-962
22. Christophe O, Rouault C, Obert B, et al: A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509 -Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol 1995; 90:195-203
23. De Vleeschauwer A, Devreese K: Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17:353-358
24. Sucker C, Senft B, Scharf RE, et al: Determination of von Willebrand factor activity: Evaluation of the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006; 12:305-310
25. Bernardo A, Ball C, Nolasco L, et al: Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood 2004; 104:100-106
26. Levi M: Platelets. Crit Care Med 2005; 33(12 Suppl):S523-S525
27. Chong AY, Lip GYH, Freestone B, et al: Increased circulating endothelial cells in acute heart failure: Comparison with von Willebrand factor and soluble E-selectin. Eur J Heart Fail 2006; 8:167-172
28. Cella G, Sbarai A, Mazzaro G, et al: Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 2001; 7:205-208
29. Bouchama A, Knochel JP: Heat stroke. N Engl J Med 2002; 346:1978-1988
30. Dong J-f, Moake JL, Bernardo A, et al: ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278:29633-29639
31. Majerus EM, Anderson PJ, Sadler JE: Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280:21773-21778
32. Furlan M, Robles R, Galbusera M, et al: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584
33. Zhou W, Inada M, Lee TP, et al: ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85:780-788
34. Uemura M, Tatsumi K, Matsumoto M, et al: Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106:922-924
35. Shang D, Zheng XW, Niiya M, et al: Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108:2207-2215
36. Crawley JT, Lam JK, Rance JB, et al: Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105:1085-1093
37. Kinasewitz GT, Yan SB, Basson B, et al: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative microorganism. Crit Care 2004; 8:R82-R90
38. Chion CKNK, Doggen CJM, Crawley JTB, et al: ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007; 109:1998-2000
39. Tsai H-M: Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med 2006; 57:419-436
40. Banno F, Kokame K, Okuda T, et al: Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107:3161-3166
41. Motto DG, Chauhan AK, Zhu G, et al: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115:2752-2761